PNB-0408 — HGF/MET Signalling Agonist
A small peptide derived from angiotensin IV research that promotes synaptogenesis — the formation of new synaptic connections — through activation of the hepatocyte growth factor (HGF) and MET receptor pathway. Estimated in preclinical research to be up to 10 million times more potent than BDNF at promoting synaptic growth. Developed at Washington State University, Dihexa has generated extraordinary interest in the nootropics and cognitive enhancement community despite an almost entirely preclinical evidence base.
01 — Research Summary
Dihexa's evidence base is almost entirely preclinical, but the animal data is remarkable — demonstrating cognitive rescue in Alzheimer's models, synaptogenesis, and potency estimates that have generated significant scientific and community interest.
Cognitive rescue in aged and Alzheimer's model animals. The original Washington State University research demonstrated Dihexa rescued spatial memory and learning in aged rats and Alzheimer's model animals at extraordinarily low doses — the paper that launched community interest and remains the primary evidence anchor.
Dramatically increased dendritic spine density. Follow-up research confirmed Dihexa significantly increases dendritic spine density — the physical substrate of synaptic connections — in hippocampal neurons. This structural synaptic growth mechanism distinguishes it from compounds that merely modulate existing neurotransmission.
HGF/MET receptor activation confirmed as primary mechanism. Mechanistic research established that Dihexa acts as an HGF/MET signalling agonist — binding a receptor complex involved in neuronal survival, growth, and synaptogenesis. The potency relative to BDNF stems from its high affinity for this pathway.
Neuroprotective effects in dopaminergic neurons. Animal research in Parkinson's models showed Dihexa protected dopaminergic neurons from toxin-induced damage, expanding the potential neuroprotective application beyond Alzheimer's pathology.
02 — Mechanism of Action
Dihexa works through a pathway that promotes the physical growth of new synaptic connections — making it mechanistically distinct from most cognitive compounds that work by modulating existing neurotransmission.
Dihexa activates the hepatocyte growth factor (HGF) receptor, MET — a receptor tyrosine kinase expressed widely in the brain and normally activated by endogenous HGF. This pathway is involved in neuronal survival, axonal guidance, and synaptogenesis, making it a high-value cognitive target.
HGF/MET activation drives dendritic spine formation — the physical protrusions on neurons where synapses form. By increasing spine density, Dihexa promotes the formation of new synaptic connections, potentially improving the structural capacity for learning and memory.
Research suggests Dihexa interacts with or converges on BDNF signalling pathways — explaining the extraordinary potency comparison. While BDNF itself has poor CNS bioavailability, Dihexa's small molecule design allows it to engage similar downstream pathways more efficiently.
By increasing synaptic density, Dihexa creates more substrate for long-term potentiation (LTP) — the strengthening of synaptic connections that underlies learning and memory consolidation. This structural mechanism may produce more durable cognitive benefits than purely neurochemical approaches.
The '10 million times more potent than BDNF' figure comes from one comparison in the original WSU paper and refers to the effective dose at which Dihexa and BDNF produce equivalent synaptogenic effects in a specific assay. It does not mean 10 million times more effective at improving cognition overall — that is a mechanistic assay comparison, not a clinical efficacy claim. It is remarkable nonetheless, but context matters when this figure is cited.
03 — Dosing Protocols
No human dosing protocol exists. Community protocols are adapted from animal study dose calculations and self-experimentation reports. Dihexa is active at very low doses — this is not a compound where more is better.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Community oral | 4–10 mg | 2–3x per week | 4–8 week cycles | Most commonly reported community oral dose. Cycling strongly recommended — effects may persist beyond dosing period. |
| Transdermal | 8–16 mg | 2–3x per week | 4–8 week cycles | DMSO-based transdermal solution. Some users prefer this route for absorption certainty. |
| Conservative start | 2–4 mg | Once per week | 4 weeks | Ultra-conservative approach given absence of human safety data. Assess cognitive response before escalating. |
Dihexa has essentially no human safety data. The HGF/MET pathway has known involvement in cancer cell proliferation — the theoretical oncological risk is the primary safety concern and is frequently discussed in the community. This is not a compound to approach casually. Anyone with cancer history or elevated cancer risk should not use Dihexa without medical consultation. Cycle with long breaks.
04 — Community Experiences
Dihexa has one of the most intellectually engaged communities of any compound on this site — primarily experienced nootropics users who have exhausted mainstream cognitive compounds and are exploring frontier territory. Discussions on r/nootropics are notable for their scientific depth and unusual honesty about the evidence gaps and the cancer risk concern.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"The cognitive clarity during active dosing is real and distinct from stimulants — it's more structural, like information retrieval is faster and more organised. The effects seem to persist beyond dosing days. I cycle 3 weeks on, 3 weeks off and track carefully..."
"HGF/MET is a known oncogene pathway. The concern is real, not theoretical. At low doses and with cycling the risk is likely low but it is not zero. Anyone with cancer history should not touch this. For healthy individuals making an informed choice, the risk profile is manageable but not zero..."
"Different profiles. Semax: acute focus and verbal fluency, shorter duration. Cerebrolysin: deeper structural improvement, longer cycle required. Dihexa: most subtle but potentially most structural — feels like the underlying processing architecture improving rather than a surface effect..."
"The synthesis is complex. Most vendors are not producing this correctly. Unlike most peptides where wrong product just means ineffective, Dihexa at wrong concentration in either direction could be problematic. Triple-check COAs and source from vendors with a track record..."